Friends of Cancer Research

Patient advocates! Join us November 17 for a webinar unpacking key discussions from our Annual Meeting on early-phase #cancer drug development and what they mean for patients. Submit your questions for the live Q&A! #patientadvocacy

Register: bit.ly/45Dkcj3.

More than a decade after its creation, the BQP remains unpredictable and underused. With only 12 of the 107 projects reaching full qualification, Congress has the opportunity to help modernize the BQP. Explore our solutions and what it means for patients: friendsofcancerresearch.org/bqp/.

Our Annual Meeting white papers take an in-depth look at each session: nonclinical strategies, first-in-human studies, and MIDD and AI for dosing in early-phase oncology development. Read the white papers and register for the meeting on 11/10. bit.ly/464kdfT #FriendsAM26

To close out our Annual Meeting, @RepMGriffith and @RepAuchincloss senior congressional staff will discuss a bipartisan legislative proposal addressing challenges and support a federal approach to improve U.S. clinical trials. Register today: bit.ly/4d4ShfE.

Read the @GoHealio article featuring our landscape assessment of 150+ studies finding that #ctDNA reductions are associated with improved OS across solid cancer types, despite differences in assays, time points, and definitions of molecular response: bit.ly/4yF4vmX.